ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hakim, M.
Right arrow Articles by English, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hakim, M.
Right arrow Articles by English, T.

The Annals of Thoracic Surgery, Vol 46, 495-501, Copyright © 1988 by The Society of Thoracic Surgeons


ARTICLES

Cyclosporin A in cardiac transplantation: medium-term results in 62 patients

M Hakim, J Wallwork and T English
Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge, England.

Between March, 1982, and October, 1984, 62 patients underwent orthotopic cardiac transplantation in our institution. Immunosuppression was based on cyclosporin A (Cy A) and low-dose steroids with an initial 10-day course of antithymocyte globulin. Follow-up ranged between 39 and 71 months (mean, 51.7 months). Actuarial survival at 1 year through 5 years was 80.6%, 77.4%, 74.2%, 71.4%, and 63.5%, respectively. Graft atheroma led to graft failure in 6 patients, 4 of whom died between 23 and 55 months after transplantation and 2 of whom had a repeat transplantation at 32 and 53 months. Diastolic hypertension (90 mm Hg or higher) developed in 88% of patients at 1 year. Chronic renal impairment was evident in all patients who survived for 2 years. Mean serum creatinine preoperatively and at 1 year through 4 years was 1.49 +/- 0.08 mg/100 ml (+/- the standard error), 2.01 +/- 0.09 mg/100 2.07 +/- 0.09 mg/100 ml, 2.26 +/- 0.19 mg/100 ml, and 2.32 +/- 0.33 mg/100 ml, respectively. End-stage renal failure requiring regular hemodialysis developed in 3 patients, 2 of whom died. We conclude that in addition to graft atheroma, Cy A- related nephrotoxicity is emerging as a major cause of medium-term and long-term morbidity and mortality. The use of lower doses of Cy A in a triple-therapy protocol, that is, Cy A, azathioprine, and low-dose steroids, could help reduce the extent of renal impairment.


This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
H. Holschermann, R. M. Bohle, H. Zeller, H. Schmidt, U. Stahl, L. Fink, H. Grimm, H. Tillmanns, and W. Haberbosch
In Situ Detection of Tissue Factor within the Coronary Intima in Rat Cardiac Allograft Vasculopathy
Am. J. Pathol., January 1, 1999; 154(1): 211 - 220.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
P. Ferraro, M. Carrier, M. White, G. B. Pelletier, and L. C. Pelletier
Antithymocyte Globulin and Methotrexate Therapy of Severe or Persistent Cardiac Allograft Rejection
Ann. Thorac. Surg., August 1, 1995; 60(2): 372 - 376.
[Abstract] [Full Text]


Home page
CLIN PEDIATRHome page
A. Larsen and J. D. Tobias
Nicardipine for the Treatment of Hypertension Following Cardiac Transplantation in a 14-Year-Old Boy
Clinical Pediatrics, May 1, 1994; 33(5): 309 - 311.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1988 by The Society of Thoracic Surgeons.